ACADIA Pharmaceuticals Inc. (ACAD)

26.10
1.12 4.11
NASDAQ : Health Technology
Prev Close 27.22
Open 27.05
Day Low/High 25.97 / 27.38
52 Wk Low/High 12.77 / 27.77
Volume 1.46M
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 143.88M
Market Cap 3.87B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ACADIA Pharmaceuticals To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results On February 26, 2019

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results On February 26, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 9, 2019

ACADIA Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 9, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its...

Berkshire Hathaway, Oneok, FNB Corp.: 'Mad Money' Lightning Round

Berkshire Hathaway, Oneok, FNB Corp.: 'Mad Money' Lightning Round

Berkshire Hathaway, Oneok, FNB Corp., Axon Enterprises, Copa Holdings, Acadia Pharamaceuticals, Delta Airlines and more.

Fed Fuels This Rally: Cramer's 'Mad Money' Recap (Wednesday 11/28/18)

Fed Fuels This Rally: Cramer's 'Mad Money' Recap (Wednesday 11/28/18)

Jim Cramer says if we have a slowdown, don't blame Powell and the Fed. Instead, keep your eyes on the G-20 and trade issues.

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to...

Interesting ACAD Put And Call Options For January 2019

Interesting ACAD Put And Call Options For January 2019

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD) study in major depressive disorder (MDD).

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S.

Interesting ACAD Put And Call Options For June 2019

Interesting ACAD Put And Call Options For June 2019

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dropbox, XPO Logistics, Ford Motor Co., Acadia Pharmaceuticals, Avalara, and more.

ACADIA Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 6, 2018

ACADIA Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 6, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Announces Executive Appointments To Lead Medical Affairs And Science

ACADIA Pharmaceuticals Announces Executive Appointments To Lead Medical Affairs And Science

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced two executive...

ACADIA Pharmaceuticals To Present At The 2018 Cantor Global Healthcare Conference On October 2, 2018

ACADIA Pharmaceuticals To Present At The 2018 Cantor Global Healthcare Conference On October 2, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

8 Stocks Poised to Change Direction

8 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

FDA Issues Statement Reaffirming The Positive Benefit-Risk Profile Of NUPLAZID® (pimavanserin) For Patients With Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson's disease...

Interesting ACAD Put And Call Options For January 2021

Interesting ACAD Put And Call Options For January 2021

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc.

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Investors: The Law Offices Of Howard G. Smith Reminds Investors Of Lead Plaintiff Deadline In The Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)

Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc.

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

Analyses Of Pimavanserin Studies Evaluating Treatment In Alzheimer's Disease Psychosis And Parkinson's Disease Psychosis Published In The Journal Of Prevention Of Alzheimer's Disease Suggest Potential For Treating Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimer's...

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals To Present At The Morgan Stanley 16th Annual Global Healthcare Conference On September 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.